Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen: Phase II - Sofia ref.: 115861 | EBOVAC2 | Project | Results | H2020 | CORDIS

Rezultaty

Ebola project clustering activity plan

Migration

Capacity-building programme

Migration

Capacity-building implementation report

Migration

Communication tools

Migration

1st EBOVAC2 e-newsletter

Migration

Publikacje

Durable natural killer cell responses after heterologous two-dose Ebola vaccination

Autorzy: Helen R. Wagstaffe, Giada Susannini, Rodolphe Thiébaut, Laura Richert, Yves Lévy, Viki Bockstal, Jeroen N. Stoop, Kerstin Luhn, Macaya Douoguih, Eleanor M. Riley, Christine Lacabaratz, Martin R. Goodier
Opublikowane w: npj Vaccines, Numer 6/1, 2021, ISSN 2059-0105
Wydawca: Nature Partners Journal
DOI: 10.1038/s41541-021-00280-0

Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination

Autorzy: Helen R Wagstaffe, Elizabeth A Clutterbuck, Viki Bockstal, Jeroen N Stoop, Kerstin Luhn, Macaya Douoguih, Georgi Shukarev, Matthew D Snape, Andrew J Pollard, Eleanor M Riley, Martin R Goodier
Opublikowane w: The Journal of Infectious Diseases, Numer 223/7, 2019, Strona(/y) 1171-1182, ISSN 0022-1899
Wydawca: University of Chicago Press
DOI: 10.1093/infdis/jiz657

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

Autorzy: Andrew J Pollard, Odile Launay, Jean-Daniel Lelievre, Christine Lacabaratz, Sophie Grande, Neil Goldstein, Cynthia Robinson, Auguste Gaddah, Viki Bockstal, Aurelie Wiedemann, Maarten Leyssen, Kerstin Luhn, Laura Richert, Christine Bétard, Malick M Gibani, Elizabeth A Clutterbuck, Matthew D Snape, Yves Levy, Macaya Douoguih, Rodolphe Thiebaut, Christopher McShane, Benoit Callendret, Stephanie Dinc
Opublikowane w: The Lancet Infectious Diseases, Numer 21/4, 2021, Strona(/y) 493-506, ISSN 1473-3099
Wydawca: The Lancet Publishing Group
DOI: 10.1016/s1473-3099(20)30476-x

Ebola virus glycoprotein stimulates IL-18–dependent natural killer cell responses

Autorzy: Helen R. Wagstaffe, Elizabeth A. Clutterbuck, Viki Bockstal, Jeroen N. Stoop, Kerstin Luhn, Macaya Douoguih, Georgi Shukarev, Matthew D. Snape, Andrew J. Pollard, Eleanor M. Riley, Martin R. Goodier
Opublikowane w: Journal of Clinical Investigation, Numer 130/7, 2020, Strona(/y) 3936-3946, ISSN 0021-9738
Wydawca: American Society for Clinical Investigation
DOI: 10.1172/jci132438

1-Barrières et facilitateurs de la mise en oeuvre d’un essai vaccinal en situation d’urgence: cas de l’essai EBOVAC2 au Burkina Faso. 2- Barriers and facilitators in implementin g a vaccine trial in emergency situation: the case of EBOLA Vaccine Phase II Trial (VAC52150 EBL2002) in Burkina Faso

Autorzy: Barry H, Valéa I, Berthé A, Lougué G, Tinto H, Thiébaut R, et al.
Opublikowane w: Numer 3-6 may 2016; 26 to 28 May 2016., 2016
Wydawca: n/a

Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen: Phase II - Sofia ref.: 115861

Rezultaty

Publikacje

Udostępnij tę stronę

Pobierz